5-({4-[(2-Carboxyethyl)carbamoyl]phenyl}diazenyl)-2-hydroxybenzoic acid

HCID 54585CAS 80573-04-2

Completing data — usually done within a minute

Basic information

Standard SMILES
O=C(O)CCNC(=O)c1ccc(N=Nc2ccc(O)c(C(=O)O)c2)cc1
InChIKey
IPOKCKJONYRRHP-UHFFFAOYSA-N
Molecular formula
C17H15N3O6
Average molar mass
357.322 g/mol
Monoisotopic mass
357.0960852

Names & identifiers

Preferred name
5-({4-[(2-Carboxyethyl)carbamoyl]phenyl}diazenyl)-2-hydroxybenzoic acid
IUPAC
5-({4-[(2-Carboxyethyl)carbamoyl]phenyl}diazenyl)-2-hydroxybenzoic acid
English name
Balsalazide
Molecular formula
C17H15N3O6
Molecular weight
357.32

Names & synonyms

GiazoCS-1360balsalazidoBALSALAZIDEBalsalazineBalsalazidumCOLAZALGIAZOBalsalazide D4Balsalazide 98%BALSALAZIDE SODIUM

Database identifiers

CAS
80573-04-2
PubChem CID
54585
DTXSID
DTXSID50861027
ChEMBL
CHEMBL1208641
ChEBI
CHEBI:267413
UNII
P80AL8J7ZP

Properties

Physicochemical properties

Melting point
254 · 254-255C
Boiling point
729.6 · 729.6±60.0 °C(Predicted)
Density
1.44 · 1.44±0.1 g/cm3(Predicted)
vapor pressure
0 Pa · 0Pa at 20℃
storage temp.
-20 °C · -20°C Freezer
solubility
DMSO (Slightly), Methanol (Slightly)

Safety & regulation

Safety data

REACH Registrations
Active

Chemistry & industry

Applications · 4 items

DescriptionColazide was launched in the UK for mild to moderate acute attacks of ulcerative colitis. It can be prepared by diazotization of 3-(4-aminobenzoylamino) propionic acid followed by condensation with salicylic acid. Colazide, an analogue of sulfasalazine, was found to be non-toxic and non-mutagenic in the Ames test. Once ingested the molecule releases a non-toxic fragment, 4-aminobenzoyl-β-alanine (poorly absorbed - 75% excretion in stool), and the active component 5- aminosalicylic acid (Mesalazine). The exact mechanism of action is not clearly understood but it is cytoprotective and has antiinflammatory properties. Other biological effects have been observed and include the following: (a) granulocyte activation is blocked, (b) there is a reduction in myeloperoxidase activity, and (c) a reduction in the release of arachidonic acid with a concomitant decrease in prostaglandin and leucotriene (as indicated by the lack of production of LTB4) production. It can behave as a reactive oxygen species (ROS) scavenger, inhibit PAF formation, reduce IL-1 production, and antagonize TNF and NK cells. While comparable in efficacy to sulfasalazine, Colazide removes the possibility of sulfasalazine side-effects, such as, agranulocytosis, hepatotoxicity and male infertility.

DescriptionBalsalazide is a prodrug form of 5-aminosalicylic acid (5-ASA; ). It is cleaved by bacterial azoreductases in the intestinal lumen to release 5-ASA. Balsalazide (600 mg/kg per day) decreases IL-2 levels and increases IL-6 levels in the serum and colonic mucosa membrane, as well as decreases micro- and macroscopic colonic damage, in a rat model of colitis induced by 2,4-dinitrochlorobenzene (DNCB). Formulations containing balsalazide have been used in the treatment of ulcerative colitis.

UsesBalsalazide-d4 is an isotopically labelled analog of Balsalazide (B116300), which is an analogue of Sulfasalazine (S699084). A prodrug of 5-aminosalicylic acid where carrier molecule is 4-aminobenzoyl-β-alanine. Anti-inflammatory (gastrointestinal).

UsesAn analogue of Sulfasalazine, A prodrug of 5-Aminosalicylic Acid

Upstream & downstream products

Suppliers50 total

北京华美互利生物化工010-56205725 · [email protected]
陕西缔都新材料有限公司81124267 17392282731 · [email protected]
济南百隆化学有限公司[email protected] · [email protected]
广州隽沐生物科技股份有限公司020-36607679; 13502246435 · [email protected]
上海毕得医药科技股份有限公司400-1647117 13681763483 · [email protected]

Additional notes

DefinitionChEBI: A monohydroxybenzoic acid consisting of 5-aminosalicylic acid (mesalazine) linked to 4-aminobenzoyl-beta-alanine via an azo bond.

Related reactions

5 records

Linked notes

Loading…